Tax is the drug again as US rival bids £27bn for Shire

 

Deputy Business editor

A second US drugs company has followed Pfizer in trying to buy a FTSE 100 giant in the hope of moving its tax base to Britain. AbbVie, until recently a division of Abbot Laboratories, has offered £27bn to buy Shire Pharmaceuticals, famed for its medicines for attention deficit disorder and rare diseases.

Shire moved to Ireland in 2008 to save tax but, just like Pfizer with AstraZeneca, AbbVie wants to merge its operations and move the domicile to the UK so it can benefit from Britain’s new-found tax- haven status.

The tax trick would not work if the combined group remained in Ireland, because US laws mean companies can only carry out such “inversion” deals with their tax domicile if at least a fifth of their shareholders are based in the new country.

UK corporate taxes are lower than in most developed economies, while patented products such as medicines carry further tax breaks.

Shire said it had rejected offers from AbbVie on 5 May, 13 May and 30 May, claiming they “fundamentally” undervalued its prospects. For the first time, it declared it would double sales to $10m (£6m) by 2020.

Shire says its fortunes have been transformed by its move into rare diseases, where sales of its medicines are running 39 per cent above last year.

AbbVie’s offer was priced at £46.11 per Shire share in cash and paper. Although based in Ireland now, Shire’s shares still trade on the London Stock Exchange.

While the takeover appears to have the hallmarks of the AstraZeneca takeover tussle, it does not have the same political ramifications.

Unlike AstraZeneca, Shire has no significant research and development presence in the UK, only employing about 400 staff in its Basingstoke head office. Its R&D scientists, who number about 1,700, are mostly in Massachusetts.

Nevertheless, AbbVie has hired the same political and media advisers as Pfizer used on its own bid – Sir Alan Parker’s Brunswick. Again like Pfizer, its panel of advisers include JPMorgan. Shire is using the banks Citi, Evercore and Morgan Stanley for its defence.

AbbVie’s blockbuster medicine is a treatment for rheumatoid arthritis called Humira, which is by some counts the biggest-selling medicine in the world. But this will begin losing its patent protection in the US and Europe in the next few years, and analysts said yesterday that Shire would provide AbbVie with the diversification it needs.

Shire’s share price leapt  17 per cent to 4,371p yesterday, and those close to the US company said it was considering a higher offer, possibly as early as next week.

At the latest price, the personal stake of Shire’s chief executive, Flemming Ornskov, would be worth £1m and his options would have a value of just under £2m.

Start your day with The Independent, sign up for daily news emails
ebooks
ebooksA special investigation by Andy McSmith
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

Guru Careers: Pricing Analyst

£30 - 35k (DOE): Guru Careers: We are seeking a Pricing Analyst with experienc...

Ashdown Group: Treasury Assistant - Accounts Assistant - London, Old Street

£24000 - £26000 per annum + benefits : Ashdown Group: A highly successful, glo...

Ashdown Group: Sales Team Leader - Wakefield, West Yorkshire

£21000 - £24000 per annum: Ashdown Group: The Ashdown Group has been engaged b...

Day In a Page

Revealed: Why Mohammed Emwazi chose the 'safe option' of fighting for Isis, rather than following his friends to al-Shabaab in Somalia

Why Mohammed Emwazi chose Isis

His friends were betrayed and killed by al-Shabaab
'The solution can never be to impassively watch on while desperate people drown'
An open letter to David Cameron: Building fortress Europe has had deadly results

Open letter to David Cameron

Building the walls of fortress Europe has had deadly results
Tory candidates' tweets not as 'spontaneous' as they seem - you don't say!

You don't say!

Tory candidates' election tweets not as 'spontaneous' as they appear
Mubi: Netflix for people who want to stop just watching trash

So what is Mubi?

Netflix for people who want to stop just watching trash all the time
The impossible job: how to follow Kevin Spacey?

The hardest job in theatre?

How to follow Kevin Spacey
Armenian genocide: To continue to deny the truth of this mass human cruelty is close to a criminal lie

Armenian genocide and the 'good Turks'

To continue to deny the truth of this mass human cruelty is close to a criminal lie
Lou Reed: The truth about the singer's upbringing beyond the biographers' and memoirists' myths

'Lou needed care, but what he got was ECT'

The truth about the singer's upbringing beyond
Migrant boat disaster: This human tragedy has been brewing for four years and EU states can't say they were not warned

This human tragedy has been brewing for years

EU states can't say they were not warned
Women's sportswear: From tackling a marathon to a jog in the park, the right kit can help

Women's sportswear

From tackling a marathon to a jog in the park, the right kit can help
Hillary Clinton's outfits will be as important as her policies in her presidential bid

Clinton's clothes

Like it or not, her outfits will be as important as her policies
NHS struggling to monitor the safety and efficacy of its services outsourced to private providers

Who's monitoring the outsourced NHS services?

A report finds that private firms are not being properly assessed for their quality of care
Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

Zac Goldsmith: 'I'll trigger a by-election over Heathrow'

The Tory MP said he did not want to stand again unless his party's manifesto ruled out a third runway. But he's doing so. Watch this space
How do Greek voters feel about Syriza's backtracking on its anti-austerity pledge?

How do Greeks feel about Syriza?

Five voters from different backgrounds tell us what they expect from Syriza's charismatic leader Alexis Tsipras
From Iraq to Libya and Syria: The wars that come back to haunt us

The wars that come back to haunt us

David Cameron should not escape blame for his role in conflicts that are still raging, argues Patrick Cockburn
Sam Baker and Lauren Laverne: Too busy to surf? Head to The Pool

Too busy to surf? Head to The Pool

A new website is trying to declutter the internet to help busy women. Holly Williams meets the founders